Impact of Aging

MS-LINK is exploring the impact of age on MS progression and treatment response.

OUTCOMES STUDY AGING IN MS ANALYSIS IMMUNOME PILOT DISCOMS EXTENSION NMSS PILOTS X 3 MS Brain Bank

Outcomes Study

This study is a multi-center observational real-world platform which aims to integrate data from multiple sources to facilitate patient and provider engagement, shared decision making, and participation in high-priority research questions, as well as identify a core set of patient reported outcomes (PROs) that correlates with disease progression and activity

Partner: Tornatore, MedStar Georgetown; English, MS Center of Atlanta

Status: Ongoing

Outcomes Study Description pdf (734.1 kB)

View

Outcomes Study Infographic pdf (2.6 MB)

View

Poster presented at AAN 2023 pdf (788.3 kB)

View

Poster presented at ECTRIMS 2023 png (1.4 MB)

View

Truven Aging in MS Analysis

Treatment and care management, clinical outcomes and mobility impairment in people with or without MS aged ≥ 50 years: observational 6-year analysis

Partner: Freeman and Lucas, UTSW Austin

Status: Complete

Impact of Aging Infographic

View

Poster presented at ACTRIMS 2020 pdf (620.2 kB)

View

Poster presented at ACTRIMS 2022 pdf (198.0 kB)

View

Manuscript doi: 10.7224/1537-2073.2021-124

Freeman L, Lucas A, Zhou J, Hayward B, Gough M, Livingston T. Outcomes and health care service use in adults 50 years or older with and without multiple sclerosis: A 6-year observational analysis. Int J MS Care. 2023;25(2):56-62. doi:10.7224/1537-2073.2021-124

Immunome Pilot

This study aims to examine the T cells, B cells, and innate immune cells of people with MS to describe age-related changes and compare them against people without MS

Partner: Bar-Or, Univ. of Pennsylvania

Status: Complete

Immunome Pilot Study Description pdf (370.5 kB)

View

Poster presented at ECTRIMS 2020 pdf (717.5 kB)

View

Zuroff L, Rezk A, Shinoda K, et al. Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. EBioMedicine. 2022;82. doi:10.1016/j.ebiom.2022.104179

DISCOMS Extension

This study aims to provide data on the durability of disease inactivity, and potential risks, after discontinuing DMT(s) in MS

Partner: Cutter, University of Alabama; Corboy, University of Colorado

Status: Complete

DISCOMS Extension Study Description pdf (359.5 kB)

View

Poster presented at ECTRIMS 2023 pdf (444.8 kB)

View

NMSS Pilots x 3

NMSS Pilot Grant 1: Cellular Senescence in Autoimmune Demyelination - This study aims to explore the role of cellular senescence in experimental autoimmune demyelination, an animal model of MS

Partner: Oksenberg, UCSF

Status: Complete

NMSS Pilot Grant 2: Determining the Effect of Circadian Rhythms in Oligodendrocyte Lineage Cell Dynamics With Age in Multiple Sclerosis: This study aims to explore the effects of circadian rhythms in oligodendrocyte lineage cell dynamics using a mouse model of MS

Partner: Gibson, Stanford University

Status: Complete

NMSS Pilot Grant 3: Association of Senescent Cells With MS progression: This study aims to explore the association between the biological age of a person with MS and their MS disease severity

Partner: Graves, UCSD

Status: Complete

NMSS Pilots Study Descriptions pdf (517.9 kB)

View

MS Brain Bank Harmonization

This study aims to explore mechanisms related to the general brain atrophy seen in MS by assembling a collection of frozen neocortical samples from 6 brain banks into a single dataset with harmonized phenotypic information and a coherent set of proteomic data

Partner: De Jager, Columbia University

Status: Ongoing

MS Brain Bank Harmonization Study Description pdf (355.1 kB)

View

Poster presented at ECTRIMS 2021 pdf (299.7 kB)

View

Welcome to MS-LINK(TM) Research

Help us direct you to the right information by selecting one of the following options:

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website.